A recent analysis supports the guided implementation of polymeric microneedle patches and GLP-1 receptor agonists, semaglutide and tirzepatide, for obesity management with an overall low risk posture. While these therapies show outstanding benefits in metabolic health and weight loss, emerging ocular safety signals necessitate ongoing pharmacovigilance and longitudinal monitoring. Stakeholders are being updated on unified findings to address obesity's complex comorbidities, ensuring a balanced approach to new treatment paradigms.
Title not available for this citation.
“Polymeric microneedle patches represent a promising noninvasive platform for the transdermal delivery of peptide and protein therapeutics, and FDA-approved polymers are widely used for this purpose.”
Title not available for this citation.
“The optimized PLGA-based microneedles exhibited uniform geometry, high drug-loading capacity, and strong mechanical integrity suitable for skin penetration.”
Title not available for this citation.
“In vivo studies demonstrated successful skin insertion and sustained peptide release for up to 72 h, supporting the potential of this platform for prolonged transdermal peptide delivery.”
Title not available for this citation.
“BS was associated with a 43% lower risk of mortality (hazard ratio [HR] .57, 95% CI .34-.95).”
Title not available for this citation.
“BS was associated with a 35% lower MACE risk (HR .65, 95% CI .51-.83).”
Title not available for this citation.
“BS was associated with a 55% lower risk of heart failure (HR .45, 95% CI .39-.51).”
Title not available for this citation.
“The GLP-1RA/GIP-RA cohort had a 12% lower risk of hypocalcemia from 0 to 1 month after surgery (relative risk [RR] 0.88; 95% CI: 0.81-0.97).”
Title not available for this citation.
“Patients with a history of GLP-1RA/GIP-RA use may experience a lower risk of short-term hypocalcemia after thyroidectomy, suggesting personalized supplementation strategies may be required for this population.”
Title not available for this citation.
“Semaglutide is currently being investigated for its effectiveness in metabolic dysfunction-associated steatotic liver disease (MASLD), irrespective of type 2 diabetes mellitus (T2DM) presence.”
Title not available for this citation.
“In multiple regression analysis, weight loss was found to independently predict improvements in aminotransferases and measured CAP (p < 0.001), irrespective of treatment duration and baseline FIB-4.”
Title not available for this citation.
“In this cohort of T2DM/MASLD patients with baseline optimal glycemic control, semaglutide-induced weight loss led to significant improvements of all hepatic parameters (biochemistry, liver stiffness, and steatosis assessed with CAP).”
Title not available for this citation.
“The intersection of obesity and asthma represents a complex clinical challenge characterized by increased symptom burden, reduced treatment efficacy, and multifactorial pathophysiology.”